IGC Pharma (NYSE American: IGC) Alzheimer's Drug Gains Attention After Ascendiant Capital Raises Price Target

IGC Pharma, Inc. (NYSE: IGC), a clinical-stage biotechnology company focused on Alzheimer's disease, artificial intelligence, and drug discovery, is drawing renewed investor attention after Ascendiant Capital reiterated its BUY rating and increased its 12-month price target to $5.50, citing multiple potential catalysts expected throughout 2026.

Investor interest has already begun to build. On June 9, 2026, shares of IGC Pharma reached an intraday high of $0.30 before closing at $0.285, with volume reaching 1,308,653 shares, well above typical trading activity. Read entire report. [https://cdn.aelieve.com/795e828b-igc-2026.06.05-q1-2026-earnings.pdf]

According to Ascendiant, the company is approaching two significant milestones expected during the second half of 2026: completion of enrollment and advancement of the Phase 2 CALMA clinical trial evaluating IGC-AD1, and the anticipated rollout of the company's proprietary AI platform beta program.

The firm's report highlights that IGC recently surpassed 80% patient enrollment in its Phase 2 CALMA study evaluating IGC-AD1 for agitation associated with Alzheimer's dementia. The company expects to complete enrollment and advance the trial during mid-to-late 2026.

Alongside IGC Pharma, Inc. (NYSE: IGC) watch CCH Holdings Ltd (NASDAQ: CCHH), Galaxy Payroll Group (NASDAQ: GLXG), Arcadia Biosciences (NASDAQ: RKDA) and Hitek Global Inc (NASDAQ: HKIT) all trading actively today.

Ascendiant also pointed to previously reported interim clinical data that demonstrated a clinically and statistically significant reduction in agitation compared with placebo among Alzheimer's patients, supporting continued development of the program.

IGC Pharma currently maintains a pipeline of five therapeutic candidates targeting Alzheimer's disease, including lead asset IGC-AD1 and TGR-63. Beyond addressing agitation symptoms, preclinical research has shown IGC-AD1 may help suppress two of the disease's primary biological hallmarks amyloid plaques and tau tangles while earlier studies suggested potential benefits in reducing agitation, anxiety, and depression.

The opportunity remains substantial. Alzheimer's disease affects millions of individuals globally and remains one of the largest unmet needs in healthcare, with limited treatment options currently available to slow progression or address the disease's underlying causes.

Ascendiant believes continued clinical progress, additional trial data, and advancement of the company's AI-powered healthcare initiatives could serve as meaningful catalysts moving forward. While acknowledging the risks associated with clinical-stage biotechnology companies, the firm noted that the potential market opportunity for successful Alzheimer's therapeutics could reach into the billions of dollars.

With major clinical milestones approaching, increasing institutional coverage, expanding intellectual property protection, and a growing focus on AI-driven biotechnology, investors continue monitoring IGC Pharma as it advances its Alzheimer's treatment pipeline and precision medicine strategy. Read entire report. [https://cdn.aelieve.com/795e828b-igc-2026.06.05-q1-2026-earnings.pdf]

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=igc-pharma-nyse-american-igc-alzheimers-drug-gains-attention-after-ascendiant-capital-raises-price-target]
Country: United States
Website: http://www.thestreetreports.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.